Aiforia launches next-generation AI technology platform
recent articles
The Ohio State University's James Cancer Hospital makes advancements on lobular breast cancer screening While researchers work to improve lobular breast cancer screening, innovative treatments are improving outcomes for patients with the...
HistoIndex to be at The Liver Meeting® (TLM) 2025 Two Posters of Distinction showcasing improved fibrosis detection in advanced MASH fibrosis and cirrhosis from two separate drug trials. These findings demonstrate the ability of...
Proscia: Expanding the industry’s most comprehensive portfolio of AI applications PHILADELPHIA and PARIS—October 15, 2025—Proscia®, a pathology AI company, will add AI biomarker detection for skin tissue to...
Indica Labs explores the capabilities and workflow of newest HALO module Highly multiplexed imaging is changing the way that we view and understand tissues and is helping to elucidate previously unrecognized cellular populations and...
Aiforia: A significant milestone in enhancing workflows and improving diagnostic quality and consistency in their pathology laboratory. Aiforia Technologies Plc, Press Release, October 13, 2025, at 10:00 a.m. EEST Aiforia Technologies’...
Lumea and Valar Labs today announced a partnership to integrate Valar Labs' Vesta tests into the Lumea digital pathology platform. LEHI, UT, UNITED STATES, October 9, 2025 /EINPresswire.com/ -- Lumea, the U.S. leader in primary clinical...
